Targeting soluble CD146 with a neutralizing antibody inhibits vascularization, growth and survival of CD146-positive tumors
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting soluble CD146 with a neutralizing antibody inhibits vascularization, growth and survival of CD146-positive tumors
Authors
Keywords
-
Journal
ONCOGENE
Volume 35, Issue 42, Pages 5489-5500
Publisher
Springer Nature
Online
2016-04-11
DOI
10.1038/onc.2016.83
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer
- (2014) M Ilie et al. BRITISH JOURNAL OF CANCER
- Secretion of interleukin-17 by CD8+ T cells expressing CD146 (MCAM)
- (2014) Pradeep K. Dagur et al. CLINICAL IMMUNOLOGY
- Angiostatin inhibits activation and migration of neutrophils
- (2013) Gurpreet K. Aulakh et al. CELL AND TISSUE RESEARCH
- Soluble Melanoma Cell Adhesion Molecule (sMCAM/sCD146) Promotes Angiogenic Effects on Endothelial Progenitor Cells through Angiomotin
- (2013) Jimmy Stalin et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- CD146 Expression Correlates with Epithelial-Mesenchymal Transition Markers and a Poor Prognosis in Gastric Cancer
- (2012) Wen-Fang Liu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CD146 gene expression in clear cell renal cell carcinoma: a potential marker for prediction of early recurrence after nephrectomy
- (2012) Gang Feng et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Tumor angiogenesis and lymphangiogenesis: Tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms
- (2012) Fausto Gueths Gomes et al. LIFE SCIENCES
- Prospective Identification of Glioblastoma Cells Generating Dormant Tumors
- (2012) Ronit Satchi-Fainaro et al. PLoS One
- CD146 Expression in Human Breast Cancer Cell Lines Induces Phenotypic and Functional Changes Observed in Epithelial to Mesenchymal Transition
- (2012) Anne-Marie Imbert et al. PLoS One
- Up-regulation of METCAM/MUC18 promotes motility, invasion, and tumorigenesis of human breast cancer cells
- (2011) Guo-fang Zeng et al. BMC CANCER
- Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
- (2011) B. Zhao et al. GENES & DEVELOPMENT
- Sirt1 deacetylates c-Myc and promotes c-Myc/Max association
- (2011) Beibei Mao et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer
- (2011) Q. Zeng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia
- (2010) K. Harhouri et al. BLOOD
- CD146 Short Isoform Increases the Proangiogenic Potential of Endothelial Progenitor Cells In Vitro and In Vivo
- (2010) Abdeldjalil Kebir et al. CIRCULATION RESEARCH
- CD146 and its Soluble Form Regulate Monocyte Transendothelial Migration
- (2009) Nathalie Bardin et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Novel Agents on the Horizon for Cancer Therapy
- (2009) W. W. Ma et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Angiomotin p80/p130 ratio: a new indicator of exercise-induced angiogenic activity in skeletal muscles from obese and non-obese rats?
- (2009) Emilie Roudier et al. JOURNAL OF PHYSIOLOGY-LONDON
- Adverse effects of anticancer agents that target the VEGF pathway
- (2009) Helen X. Chen et al. Nature Reviews Clinical Oncology
- Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels
- (2008) Shinji Ueno et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer
- (2008) Jun-Wei Liu et al. PROSTATE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now